If this is your first time accessing any of the Presentations from JADPRO Live at APSHO 2016, please take a moment to create an account using the Register link to the right. Otherwise, please log in with your username and password to proceed. Please contact firstname.lastname@example.org with any questions.
A continuing education activity for physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists.
This activity is supported by an educational grant from Bristol-Myers Squibb and Merck & Co, Inc.
Release date: January 17, 2017 Estimated time to complete activity: 0.75 hours
Expiration date: January 17, 2018
Daniel M. Siegel, MD, MS, FAAD
SUNY Downstate, SUNY Downstate Medical Center Department of Dermatology
Brianna Hoffner, MS, ANP-BC, AOCNP®
University of Colorado Cancer Center
Activity Rationale and Purpose
Skin cancer is the most common of all cancers, with melanoma the most aggressive and lethal and basal cell carcinoma the most common. The incidence of each is increasing worldwide; aging populations, changes in sun exposure habits, and environmental changes are possible reasons. Improved understanding of the mechanisms by which melanoma evades the immune system and the molecular pathways utilized has led to advances in the development of both targeted agents and immunotherapies that favorably impact morbidity and mortality. Newly emerging agents for locally-advanced and metastatic basal cell carcinoma may increasingly improve survival rates. However, these therapies may be associated with severe, and potentially lethal adverse events, which warrants judicious monitoring by the full multidisciplinary team.
The intended audience for this enduring internet activity is physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists who specialize in the field of oncology.
After completing this educational activity, participants should be able to:
- Demonstrate increased understanding of the MOAs of targeted and immunotherapy agents used in the treatment of advanced/metastatic melanoma and/or basal cell carcinoma, including the impact these unique agents have on patient outcomes
- Apply new skill sets to guide and manage treatment expectations of patients and their families
- Recognize and manage adverse events that occur with use of targeted therapies and immunotherapies in the treatment of advanced/metastatic melanoma and/or basal cell carcinoma
- Discuss the pivotal role and necessary expertise of the AP as a vital part of the collaborative oncology team treating these skin cancers
The Annenberg Center for Health Sciences at Eisenhower has been awarded Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME®)
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
A maximum of 0.75 contact hours may be earned for successful completion of this activity.
This knowledge-based accredited education lecture is intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Annenberg Center for Health Sciences at Eisenhower.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program
All individuals in positions to control the content of this activity (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Daniel M. Siegel, MD, MS, FAAD, has served on the speakers’ bureau for Genentech. He has received research support and served as a consultant for Genentech and Novartis. He has participated on advisory boards for Castle Biosciences.
Brianna Hoffner, MS, ANP-BC, AOCNP® has nothing to disclose.
Lead Nurse Planner
Wendy J. Smith ACNP, AOCN®, has nothing to disclose.
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CS, ANP, has nothing to disclose.
Lynn Rubin has nothing to disclose.
Annie Yueh has nothing to disclose.
Wendy J. Smith ACNP, AOCN®, has nothing to disclose.
Annenberg Center for Health Sciences at Eisenhower
The staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of the Annenberg Center for Health Sciences, Meniscus Educational Institute and JADPRO for all educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Meniscus Educational Institute of any specific therapeutics or approaches to diagnosis or patient management.
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
How to Earn Credit
To access the learning assessment and evaluation form online, visit education.annenberg.net/jpl16-sessions.
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment and complete and submit the evaluation form) will be able to download a statement of credit.
- 0.75 AMA PRA Category 1 Credit(s)™
- 0.75 ACPE
- 0.75 ANCC
- 0.75 Attendance